甲状腺癌是最常见的恶性内分泌肿瘤，其中甲状腺乳头状癌（PTC）是最常见的类型，占甲状腺癌病例的85%。在这里，我们对 PTC 研究中 microRNA 领域的文献进行了文献计量分析，以展示当前趋势和研究热点，并呈现过去和新兴趋势的可视化地图。我们在 Web of Scientific Core Collection (WoSCC) 数据库中搜索了以下内容： 1999 年至 2023 年的出版物主要集中在这一领域。接下来，我们使用 VOSviewer、CiteSpace 和 Microsoft Excel 2019 等可视化工具来呈现作者、机构、期刊和国家/地区贡献的同现和同被引分析、趋势、热点和可视化表示。分析涵盖1999年至2023年期间，来自54个国家/地区的994篇论文。发表论文最多和总引用率最高的国家是中华人民共和国，但美国的平均引用率最高。在前十名富有成效的机构中，俄亥俄州立大学（Ohio State Univ）是该领域最突出的贡献者。临床内分泌学杂志

Thyroid cancer is the most common malignant endocrine tumor, with papillary thyroid carcinoma (PTC) being the most prevalent type, accounting for 85% of thyroid cancer cases. Here, we conducted a bibliometric analysis of the literature in the field of microRNAs in PTC research to demonstrate current trends and research hotspots, and present a visual map of past and emerging trends.We searched the Web of Scientific Core Collection (WoSCC) database for publications from 1999 to 2023 centered on this field. Next, we employed visualization tools such as VOSviewer, CiteSpace, and Microsoft Excel 2019 to present co-occurrence and co-citation analyses, trends, hotspots, and visual representations of contributions from authors, institutions, journals, and countries/regions.The bibliometric analysis encompassed the period from 1999 to 2023, with 994 papers from 54 countries/regions. The country with the most publications and highest total citations was the People's Republic of China, but the United States held the highest average citation rate. Among the top ten productive institutions, the Ohio State University (Ohio State Univ) was the most prominent contributor to this field. The JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (J Clin Endocrinol Metab) ranked first in terms of citation counts and average citations among the top ten productive journals. In terms of keywords, "circular RNAs", "promotes", and "progression" have become prominent research areas.This study elucidates current trends, hotspots, and emerging frontiers in miRNA research within PTC, and provides new insights and guidance for future identification of new PTC biomarkers and clinical trials.© 2024 Zhang et al.